Biosimilar Contract Manufacturing Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Rheumatoid Arthritis, Others), by Region, Country, Segment, and Companies, 2024-2030
The global Biosimilar Contract Manufacturing market size is poised to register 9.38% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biosimilar Contract Manufacturing market across By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Rheumatoid Arthritis, Others).
The biosimilar contract manufacturing market is experiencing rapid growth, driven by several factors in 2024 and beyond. Biosimilars, which are highly similar versions of approved biologic drugs, offer cost-effective alternatives to branded biologics and are increasingly being adopted worldwide. Contract manufacturing organizations (CMOs) specializing in biosimilars play a crucial role in the production process, offering expertise in cell line development, process optimization, and regulatory compliance. Market growth is fueled by the increasing demand for biosimilars due to rising healthcare costs and the expiration of patents for several blockbuster biologic drugs. Moreover, advancements in bioprocessing technologies and manufacturing platforms are enabling CMOs to enhance production efficiency and reduce costs, driving market expansion. Additionally, strategic partnerships and collaborations between pharmaceutical companies and CMOs are driving innovation and capacity expansion efforts, further propelling market growth. Furthermore, regulatory initiatives aimed at streamlining the approval process for biosimilars are creating opportunities for CMOs to support biosimilar development programs, shaping industry dynamics and competitiveness.
Biosimilar Contract Manufacturing Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilar Contract Manufacturing market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilar Contract Manufacturing survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilar Contract Manufacturing industry.
Key market trends defining the global Biosimilar Contract Manufacturing demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Biosimilar Contract Manufacturing Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Biosimilar Contract Manufacturing industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilar Contract Manufacturing companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Biosimilar Contract Manufacturing industry
Leading Biosimilar Contract Manufacturing companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilar Contract Manufacturing companies.
Biosimilar Contract Manufacturing Market Study- Strategic Analysis Review
The Biosimilar Contract Manufacturing market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Biosimilar Contract Manufacturing industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Biosimilar Contract Manufacturing Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Biosimilar Contract Manufacturing Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Biosimilar Contract Manufacturing market segments. Similarly, Strong end-user demand is encouraging Canadian Biosimilar Contract Manufacturing companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Biosimilar Contract Manufacturing market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Biosimilar Contract Manufacturing Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Biosimilar Contract Manufacturing industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Biosimilar Contract Manufacturing market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilar Contract Manufacturing in Asia Pacific. In particular, China, India, and South East Asian Biosimilar Contract Manufacturing markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Biosimilar Contract Manufacturing Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Biosimilar Contract Manufacturing Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilar Contract Manufacturing market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilar Contract Manufacturing.
Biosimilar Contract Manufacturing Market Company Profiles
The global Biosimilar Contract Manufacturing market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AGC Biologics, Alcami Corp Inc, Almac Group, Avid Bioservices Inc, Biocon, Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent Inc, Element Materials Technology, Fujifilm Kyowa Kirin Biologics Co. Ltd, IQVIA Inc, Lonza, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi Biologics
Recent Biosimilar Contract Manufacturing Market Developments
The global Biosimilar Contract Manufacturing market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Biosimilar Contract Manufacturing Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Product
Recombinant Non-Glycosylated Proteins
Recombinant Glycosylated Proteins
By Production Technology
Mammalian
Non-Mammalian
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Rheumatoid Arthritis
Others
Geographical Segmentation:
AGC Biologics
Alcami Corp Inc
Almac Group
Avid Bioservices Inc
Biocon
Boehringer Ingelheim Biopharmaceuticals GmbH
Catalent Inc
Element Materials Technology
Fujifilm Kyowa Kirin Biologics Co. Ltd
IQVIA Inc
Lonza
Rentschler Biopharma SE
Samsung Biologics
Thermo Fisher Scientific Inc
WuXi Biologics
Formats Available: Excel, PDF, and PPT
The biosimilar contract manufacturing market is experiencing rapid growth, driven by several factors in 2024 and beyond. Biosimilars, which are highly similar versions of approved biologic drugs, offer cost-effective alternatives to branded biologics and are increasingly being adopted worldwide. Contract manufacturing organizations (CMOs) specializing in biosimilars play a crucial role in the production process, offering expertise in cell line development, process optimization, and regulatory compliance. Market growth is fueled by the increasing demand for biosimilars due to rising healthcare costs and the expiration of patents for several blockbuster biologic drugs. Moreover, advancements in bioprocessing technologies and manufacturing platforms are enabling CMOs to enhance production efficiency and reduce costs, driving market expansion. Additionally, strategic partnerships and collaborations between pharmaceutical companies and CMOs are driving innovation and capacity expansion efforts, further propelling market growth. Furthermore, regulatory initiatives aimed at streamlining the approval process for biosimilars are creating opportunities for CMOs to support biosimilar development programs, shaping industry dynamics and competitiveness.
Biosimilar Contract Manufacturing Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilar Contract Manufacturing market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilar Contract Manufacturing survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilar Contract Manufacturing industry.
Key market trends defining the global Biosimilar Contract Manufacturing demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Biosimilar Contract Manufacturing Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Biosimilar Contract Manufacturing industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilar Contract Manufacturing companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Biosimilar Contract Manufacturing industry
Leading Biosimilar Contract Manufacturing companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilar Contract Manufacturing companies.
Biosimilar Contract Manufacturing Market Study- Strategic Analysis Review
The Biosimilar Contract Manufacturing market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Biosimilar Contract Manufacturing industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Biosimilar Contract Manufacturing Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Biosimilar Contract Manufacturing Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Biosimilar Contract Manufacturing market segments. Similarly, Strong end-user demand is encouraging Canadian Biosimilar Contract Manufacturing companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Biosimilar Contract Manufacturing market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Biosimilar Contract Manufacturing Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Biosimilar Contract Manufacturing industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Biosimilar Contract Manufacturing market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilar Contract Manufacturing in Asia Pacific. In particular, China, India, and South East Asian Biosimilar Contract Manufacturing markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Biosimilar Contract Manufacturing Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Biosimilar Contract Manufacturing Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilar Contract Manufacturing market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilar Contract Manufacturing.
Biosimilar Contract Manufacturing Market Company Profiles
The global Biosimilar Contract Manufacturing market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AGC Biologics, Alcami Corp Inc, Almac Group, Avid Bioservices Inc, Biocon, Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent Inc, Element Materials Technology, Fujifilm Kyowa Kirin Biologics Co. Ltd, IQVIA Inc, Lonza, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi Biologics
Recent Biosimilar Contract Manufacturing Market Developments
The global Biosimilar Contract Manufacturing market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Biosimilar Contract Manufacturing Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Product
Recombinant Non-Glycosylated Proteins
Recombinant Glycosylated Proteins
By Production Technology
Mammalian
Non-Mammalian
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Rheumatoid Arthritis
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
AGC Biologics
Alcami Corp Inc
Almac Group
Avid Bioservices Inc
Biocon
Boehringer Ingelheim Biopharmaceuticals GmbH
Catalent Inc
Element Materials Technology
Fujifilm Kyowa Kirin Biologics Co. Ltd
IQVIA Inc
Lonza
Rentschler Biopharma SE
Samsung Biologics
Thermo Fisher Scientific Inc
WuXi Biologics
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Biosimilar Contract Manufacturing Market Overview and Key Findings, 2024
1.2 Biosimilar Contract Manufacturing Market Size and Growth Outlook, 2021- 2030
1.3 Biosimilar Contract Manufacturing Market Growth Opportunities to 2030
1.4 Key Biosimilar Contract Manufacturing Market Trends and Challenges
1.4.1 Biosimilar Contract Manufacturing Market Drivers and Trends
1.4.2 Biosimilar Contract Manufacturing Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Biosimilar Contract Manufacturing Companies
2. BIOSIMILAR CONTRACT MANUFACTURING MARKET SIZE OUTLOOK TO 2030
2.1 Biosimilar Contract Manufacturing Market Size Outlook, USD Million, 2021- 2030
2.2 Biosimilar Contract Manufacturing Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. BIOSIMILAR CONTRACT MANUFACTURING MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. BIOSIMILAR CONTRACT MANUFACTURING MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Recombinant Non-Glycosylated Proteins
Recombinant Glycosylated Proteins
By Production Technology
Mammalian
Non-Mammalian
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Rheumatoid Arthritis
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Biosimilar Contract Manufacturing Market, 2025
5.2 Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Biosimilar Contract Manufacturing Market, 2025
5.5 Europe Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.6 Europe Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Biosimilar Contract Manufacturing Market, 2025
5.8 North America Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.9 North America Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Biosimilar Contract Manufacturing Market, 2025
5.11 South America Pacific Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.12 South America Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Biosimilar Contract Manufacturing Market, 2025
5.14 Middle East Africa Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Biosimilar Contract Manufacturing Market Size Outlook and Revenue Growth Forecasts
6.2 US Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Biosimilar Contract Manufacturing Industry Drivers and Opportunities
7. BIOSIMILAR CONTRACT MANUFACTURING MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. BIOSIMILAR CONTRACT MANUFACTURING COMPANY PROFILES
8.1 Profiles of Leading Biosimilar Contract Manufacturing Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AGC Biologics
Alcami Corp Inc
Almac Group
Avid Bioservices Inc
Biocon
Boehringer Ingelheim Biopharmaceuticals GmbH
Catalent Inc
Element Materials Technology
Fujifilm Kyowa Kirin Biologics Co. Ltd
IQVIA Inc
Lonza
Rentschler Biopharma SE
Samsung Biologics
Thermo Fisher Scientific Inc
WuXi Biologics
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Biosimilar Contract Manufacturing Market Overview and Key Findings, 2024
1.2 Biosimilar Contract Manufacturing Market Size and Growth Outlook, 2021- 2030
1.3 Biosimilar Contract Manufacturing Market Growth Opportunities to 2030
1.4 Key Biosimilar Contract Manufacturing Market Trends and Challenges
1.4.1 Biosimilar Contract Manufacturing Market Drivers and Trends
1.4.2 Biosimilar Contract Manufacturing Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Biosimilar Contract Manufacturing Companies
2. BIOSIMILAR CONTRACT MANUFACTURING MARKET SIZE OUTLOOK TO 2030
2.1 Biosimilar Contract Manufacturing Market Size Outlook, USD Million, 2021- 2030
2.2 Biosimilar Contract Manufacturing Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. BIOSIMILAR CONTRACT MANUFACTURING MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. BIOSIMILAR CONTRACT MANUFACTURING MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Recombinant Non-Glycosylated Proteins
Recombinant Glycosylated Proteins
By Production Technology
Mammalian
Non-Mammalian
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Rheumatoid Arthritis
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Biosimilar Contract Manufacturing Market, 2025
5.2 Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Biosimilar Contract Manufacturing Market, 2025
5.5 Europe Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.6 Europe Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Biosimilar Contract Manufacturing Market, 2025
5.8 North America Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.9 North America Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Biosimilar Contract Manufacturing Market, 2025
5.11 South America Pacific Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.12 South America Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Biosimilar Contract Manufacturing Market, 2025
5.14 Middle East Africa Biosimilar Contract Manufacturing Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Biosimilar Contract Manufacturing Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Biosimilar Contract Manufacturing Market Size Outlook and Revenue Growth Forecasts
6.2 US Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Biosimilar Contract Manufacturing Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Biosimilar Contract Manufacturing Industry Drivers and Opportunities
7. BIOSIMILAR CONTRACT MANUFACTURING MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. BIOSIMILAR CONTRACT MANUFACTURING COMPANY PROFILES
8.1 Profiles of Leading Biosimilar Contract Manufacturing Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AGC Biologics
Alcami Corp Inc
Almac Group
Avid Bioservices Inc
Biocon
Boehringer Ingelheim Biopharmaceuticals GmbH
Catalent Inc
Element Materials Technology
Fujifilm Kyowa Kirin Biologics Co. Ltd
IQVIA Inc
Lonza
Rentschler Biopharma SE
Samsung Biologics
Thermo Fisher Scientific Inc
WuXi Biologics
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
